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Dear Sir,
A letter by Rashmi Ranjan Das et al. was recently pub-
lished in Infection in which the authors commented on our
article entitled ‘‘Immunogenicity of recombinant hepatitis
B vaccine: comparison of two different vaccination
schedules’’ [1]. We would like to take the opportunity
provided by this letter to discuss our ﬁndings in particular
and hepatitis B epidemiology in Turkey in general.
The study performed by Das et al. [2] is one of the few
published to date that compares different vaccination
schedules of hepatitis B immunization in children [2–4].
These authors performed a randomized clinical trial on the
immunogenicity of two different hepatitis B vaccine
schedules, i.e., birth, 6 weeks, and 14 weeks (Group A) or
6, 10, and 14 weeks (Group B), and found that serocon-
version rates for hepatitis B vaccine were comparable in
the two groups. In contrast, two other studies [3, 4], similar
to our study, revealed lesser seroconversion in infants
whose vaccination started immediately after birth. Such
data will contribute to the generation of recommendations
on the optimal timing of the initial dose of hepatitis B
immunization in infants. In addition to seroprotection,
other factors, such as the feasibility of screening for hep-
atitis B virus surface antigen (HBsAg) in pregnancy and
changing epidemiology of the disease in vaccinated pop-
ulations will also have an effect on these recommendations.
With respect to hepatitis B epidemiology in Turkey, we
agree with the conclusions of Das et al. [2]. It is likely that
vaccinated children born to HBsAg-positive mothers or
living in areas where hepatitis B infection is endemic are
exposed to hepatitis B throughout childhood. Such children
can obtain natural booster doses, which is also an approach
to be considered in countries with moderate endemicity.
Turkey is known to have moderate hepatitis B endemicity,
but in the previous decade the prevalence of HBsAg pos-
itivity declined from 4.19 to 2.10 [5–8]. Although hepatitis
B infection seroprevalances are accepted to have increased
in the more eastern regions in Turkey relative to the wes-
tern ones, a recent study found that the incidence of hep-
atitis B carriers in pregnancy was 2.1% in southeastern
regions of Turkey [9]. This decrease is the result of the
implementation of hepatitis B vaccination programs for
infants in 1998 and catch-up vaccination programs for
school-age children. According to Turkish Ministry of
Health data, the hepatitis B coverage rate for infants
\1 year of age in 2010 was 95%, and incidences of HBsAg
positivity for children\5 years of age were 3/100,000 and
0.5/100,000 in 2005 and 2010, respectively [10]. Turkey is
shifting from moderate to low endemicity and, conse-
quently, the possibility of repeated sub-clinical exposure
and natural boosters is also decreasing. These facts support
the comment made in our study ‘‘as children need long-
term protectivity and if immunological memory may later
decline or become undetectable, the risk of breakthrough
infection may occur’’.
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DOI 10.1007/s15010-011-0133-5Infants born to HBsAg-positive mothers should receive
the ﬁrst dose of hepatitis B vaccine at birth, but the ﬁrst
dose may be given at a later age for other children. How-
ever, screening is costly and not usually feasible in Turkey.
In countries where screening programs for pregnancy are
not available, vaccination at birth for hepatitis B perinatal
infections is still a necessity. We agree with Das et al. [2]
on the necessity of post-vaccination follow-up of different
schedules, including birth dose of vaccination with sero-
epidemiological studies. As we emphasized previously, our
study is a preliminary report and we plan to follow up these
infants until puberty and evaluate their immunological
status.
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